Talphera, Inc. TLPH
Biotechnology: Pharmaceutical Preparations · IPO 2011 · data as of November 13, 2026
Talphera, Inc. (TLPH) is a healthcare company listed in the US with a market value of about $47M. In fiscal year 2025 it had revenue of $28000 and net income of -$14M, a net margin of -51035.7%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -65% a year, a 5-year average ROIC of -103%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Talphera
Talphera is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2011. Revenue went from $5M in 2014 to $28000 in 2025, a decline of about 37.8% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 473% over three years (dilution for shareholders). It spends 21546% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28000 | $0 | $651000 | — | $3M | $5M | $2M | $2M | $8M | $17M |
| Net income | -$14M | -$13M | -$18M | $48M | -$35M | -$40M | -$53M | -$47M | -$52M | -$43M |
| Free cash flow | — | -$13M | -$18M | -$29M | -$32M | -$40M | -$55M | -$30M | -$32M | -$33M |
| EPS (diluted) | $-0.34 | $-0.50 | $-1.29 | $5.72 | $-5.86 | $-0.47 | $-0.67 | $-0.81 | $-1.10 | $-0.95 |
| Net margin | -51035.7% | — | -2826.0% | — | -1245.5% | -745.5% | -2325.9% | -2192.0% | -644.2% | -248.6% |
| ROIC | -62.5% | -150.6% | -119.7% | -78.5% | — | — | — | -173.8% | — | -197.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $3.12, 245% above the current price; targets range from $3.00 to $3.50; the consensus rating is “none”; expected EPS is $-0.26 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Talphera stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Talphera pay a dividend?
Not currently.
Is Talphera a good stock to buy?
We do not give buy or sell advice. Talphera scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.